Value Fund L. P. Biotechnology Buys 100,000 Shares of Infinity Pharmaceuticals Inc. (INFI) Stock

Infinity Pharmaceuticals Inc. (NASDAQ:INFI) major shareholder Value Fund L. P. Biotechnology bought 100,000 shares of the business’s stock in a transaction on Wednesday, November 28th. The shares were acquired at an average cost of $1.30 per share, for a total transaction of $130,000.00. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Major shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

NASDAQ INFI opened at $1.33 on Monday. Infinity Pharmaceuticals Inc. has a one year low of $1.22 and a one year high of $2.92.

Infinity Pharmaceuticals (NASDAQ:INFI) last posted its earnings results on Monday, November 5th. The biotechnology company reported $0.23 EPS for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.37. The business had revenue of $22.00 million for the quarter. As a group, research analysts expect that Infinity Pharmaceuticals Inc. will post -0.23 earnings per share for the current year.

A number of hedge funds and other institutional investors have recently bought and sold shares of INFI. Acadian Asset Management LLC increased its position in Infinity Pharmaceuticals by 95.2% during the 2nd quarter. Acadian Asset Management LLC now owns 372,009 shares of the biotechnology company’s stock valued at $711,000 after purchasing an additional 181,436 shares during the period. Algert Global LLC purchased a new position in shares of Infinity Pharmaceuticals in the 2nd quarter worth approximately $139,000. Dimensional Fund Advisors LP grew its position in shares of Infinity Pharmaceuticals by 27.0% in the 2nd quarter. Dimensional Fund Advisors LP now owns 932,370 shares of the biotechnology company’s stock worth $1,781,000 after buying an additional 198,098 shares during the last quarter. Essex Investment Management Co. LLC grew its position in shares of Infinity Pharmaceuticals by 121.4% in the 3rd quarter. Essex Investment Management Co. LLC now owns 364,401 shares of the biotechnology company’s stock worth $988,000 after buying an additional 199,796 shares during the last quarter. Finally, Northpointe Capital LLC purchased a new position in shares of Infinity Pharmaceuticals in the 3rd quarter worth approximately $1,433,000. 52.16% of the stock is currently owned by institutional investors and hedge funds.

A number of research analysts have commented on the stock. Wells Fargo & Co downgraded shares of Infinity Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Monday, November 12th. JPMorgan Chase & Co. downgraded shares of Infinity Pharmaceuticals from a “neutral” rating to an “underweight” rating in a research report on Monday, November 12th. Finally, Zacks Investment Research downgraded shares of Infinity Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, October 9th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and one has issued a buy rating to the company. The company has a consensus rating of “Hold” and a consensus price target of $3.50.

COPYRIGHT VIOLATION NOTICE: “Value Fund L. P. Biotechnology Buys 100,000 Shares of Infinity Pharmaceuticals Inc. (INFI) Stock” was originally posted by Community Financial News and is the property of of Community Financial News. If you are viewing this piece of content on another site, it was illegally copied and republished in violation of US and international trademark and copyright laws. The original version of this piece of content can be viewed at https://www.com-unik.info/2018/12/03/value-fund-l-p-biotechnology-buys-100000-shares-of-infinity-pharmaceuticals-inc-infi-stock.html.

About Infinity Pharmaceuticals

Infinity Pharmaceuticals, Inc, a biopharmaceutical company, develops medicines for people with cancer in the United States. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma), which is in Phase 1/1b clinical study.

Further Reading: Swap

Insider Buying and Selling by Quarter for Infinity Pharmaceuticals (NASDAQ:INFI)

Receive News & Ratings for Infinity Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Infinity Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit